Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

ximum tolerated dose (MTD) has not been reached and the study continues to accrue patients.

"Our Fleximer nanotechnology platform is designed to create proprietary new drugs from existing and novel pharmaceutical compounds," said Julie Olson, President and Chief Executive Officer of Mersana. "We are pleased to note that in the Phase I study, our proprietary Fleximer-controlled drug release system achieved results consistent with our objective of extending the half-life of the camptothecin analog while avoiding safety concerns. The favorable pharmacokinetic and safety data are consistent with results from preclinical studies of XMT-1001," she concluded.

About XMT-1001

XMT-1001 is Mersana's most advanced Fleximer(TM)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer

Mersana is transforming oncology product development by creating new drugs from anti-cancer agents through application of its Fleximer nanotechnology platform. Fleximer is a novel, biodegradable and bio-inert polymer that can be chemically linked to drugs, including small chemical entities, peptides and biologics. Fleximer-based compounds can be individually designed to improve the therapeutic performance of drugs by modulating such properties as circulation time and site of release, while significantly improving toxicity profiles.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key com
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers ... technologies must be able to protect their ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... of the Medical Device Industry, it steadfastly ... sectors of cases involving IP infringement. This ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ... cells. VSRNAs are of molecular size less than 10 ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ... growth of these markets. The European ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... the answer to one open-ended question predicted the teenagers, offending ... think you,ll live?", According to the study, having little hope ... Piquero said the study found those who don,t view a ... rates and commit more serious offenses, while those who believe ... less., "In a lot of distressed communities and for a ...
(Date:4/14/2014)... a molecule that is a probable driving force in ... an important target for colorectal cancer treatment and a ... microRNA-135b (miR-135b) in two animal models and human tumors ... and was led by researchers at The Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
(Date:4/14/2014)... Depression can hit young fathers hard -- with symptoms increasing ... children,s lives, a new Northwestern Medicine study has found. , ... first five years of fatherhood for these young men, who ... whom lived in the same home as their children. The ... journal Pediatrics . , This study is the first ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... to Accelerate Sales of the New, Fully Nano-Encapsulated Liquid Vitamin, ... and COLUMBUS, Ohio, June 23 livethesource(TM) announced ... has joined the company,s distribution network to help ... its breakthrough technology, daily source(TM) is a complete ...
... suggests a direct link between smoking and brain damage will ... of Neurochemistry . Researchers, led by Debapriya Ghosh and Dr ... have found that a compound in tobacco provokes white blood ... leading to severe neurological damage. The research centers ...
... Each year hospital operating rooms face increasingly difficult ... more demanding. Saint Vincent Health Center (SVHC) in ... provided by Eclipsys Corp. and powered by Surgical Information ... and national averages for quality measures. , , ...
... Derma Sciences, Inc. (OTC ... products, announced today that it has begun shipping BIOGUARD(TM) ... that it has been awarded reimbursement codes for the ... BIOGUARD will offer surgeons, wound care clinicians, infection ...
... WASHINGTON, June 23 A study released earlier this month ... Ohio University found that medical bills are involved ... 50 percent just six years ago. Additionally, more than 75 ... overwhelmed by the out-of-pocket expenses. In the wake of these ...
... Center offers more services to autistic community with the help ... Judson Center ( www.judsoncenter.org ), a comprehensive ... of individuals and families, today opens the newly-constructed Autism Center ... headquarters. Judson Center employees, autism advocates and families as ...
Cached Medicine News:Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 2Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 3Health News:New research discovers link between smoking and brain damage 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 2Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 3Health News:Judson Center Celebrates Grand Opening of its New Autism Center 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: